Advertisement
Research Article

The Novel Deacetylase Inhibitor AR-42 Demonstrates Pre-Clinical Activity in B-Cell Malignancies In Vitro and In Vivo

  • David M. Lucas,

    Affiliations: Department of Internal Medicine, The Ohio State University, Columbus, Ohio, United States of America, College of Pharmacy, The Ohio State University, Columbus, Ohio, United States of America

    X
  • Lapo Alinari,

    Affiliation: Department of Internal Medicine, The Ohio State University, Columbus, Ohio, United States of America

    X
  • Derek A. West,

    Affiliation: Department of Internal Medicine, The Ohio State University, Columbus, Ohio, United States of America

    X
  • Melanie E. Davis,

    Affiliation: Department of Internal Medicine, The Ohio State University, Columbus, Ohio, United States of America

    X
  • Ryan B. Edwards,

    Affiliation: Department of Internal Medicine, The Ohio State University, Columbus, Ohio, United States of America

    X
  • Amy J. Johnson,

    Affiliation: Department of Internal Medicine, The Ohio State University, Columbus, Ohio, United States of America

    X
  • Kristie A. Blum,

    Affiliation: Department of Internal Medicine, The Ohio State University, Columbus, Ohio, United States of America

    X
  • Craig C. Hofmeister,

    Affiliation: Department of Internal Medicine, The Ohio State University, Columbus, Ohio, United States of America

    X
  • Michael A. Freitas,

    Affiliation: Department of Molecular Virology, Immunology, and Medical Genetics, The Ohio State University, Columbus, Ohio, United States of America

    X
  • Mark R. Parthun,

    Affiliation: Department of Molecular and Cellular Biochemistry, The Ohio State University, Columbus, Ohio, United States of America

    X
  • Dasheng Wang,

    Affiliation: College of Pharmacy, The Ohio State University, Columbus, Ohio, United States of America

    X
  • Amy Lehman,

    Affiliation: Center for Biostatisics, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, United States of America

    X
  • Xiaoli Zhang,

    Affiliation: Center for Biostatisics, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, United States of America

    X
  • David Jarjoura,

    Affiliation: Center for Biostatisics, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, United States of America

    X
  • Samuel K. Kulp,

    Affiliation: College of Pharmacy, The Ohio State University, Columbus, Ohio, United States of America

    X
  • Carlo M. Croce,

    Affiliation: Department of Molecular Virology, Immunology, and Medical Genetics, The Ohio State University, Columbus, Ohio, United States of America

    X
  • Michael R. Grever,

    Affiliations: Department of Internal Medicine, The Ohio State University, Columbus, Ohio, United States of America, College of Pharmacy, The Ohio State University, Columbus, Ohio, United States of America

    X
  • Ching-Shih Chen,

    Affiliation: College of Pharmacy, The Ohio State University, Columbus, Ohio, United States of America

    X
  • Robert A. Baiocchi equal contributor,

    equal contributor Contributed equally to this work with: Robert A. Baiocchi, John C. Byrd

    Affiliation: Department of Internal Medicine, The Ohio State University, Columbus, Ohio, United States of America

    X
  • John C. Byrd equal contributor mail

    equal contributor Contributed equally to this work with: Robert A. Baiocchi, John C. Byrd

    john.byrd@osumc.edu

    Affiliations: Department of Internal Medicine, The Ohio State University, Columbus, Ohio, United States of America, College of Pharmacy, The Ohio State University, Columbus, Ohio, United States of America

    X
  • Published: June 03, 2010
  • DOI: 10.1371/journal.pone.0010941

About the Authors

David M. Lucas, Lapo Alinari, Derek A. West, Melanie E. Davis, Ryan B. Edwards, Amy J. Johnson, Kristie A. Blum, Craig C. Hofmeister, Michael R. Grever, Robert A. Baiocchi, John C. Byrd
Department of Internal Medicine, The Ohio State University, Columbus, Ohio, United States of America
Michael A. Freitas, Carlo M. Croce
Department of Molecular Virology, Immunology, and Medical Genetics, The Ohio State University, Columbus, Ohio, United States of America
Mark R. Parthun
Department of Molecular and Cellular Biochemistry, The Ohio State University, Columbus, Ohio, United States of America
David M. Lucas, Dasheng Wang, Samuel K. Kulp, Michael R. Grever, Ching-Shih Chen, John C. Byrd
College of Pharmacy, The Ohio State University, Columbus, Ohio, United States of America
Amy Lehman, Xiaoli Zhang, David Jarjoura
Center for Biostatisics, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, United States of America

Corresponding Author

Email: john.byrd@osumc.edu

Competing Interests

MRG served as a consultant to Arno Therapeutics. CSC received royalty payments from Arno Therapeutics per the licensing agreement of AR-42 between The Ohio State University Research Foundation and the company. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: DML LA DAW RAB JCB. Performed the experiments: LA DAW MED RBE. Analyzed the data: DML LA DAW MED RBE AJJ KAB CCH MAF MRP AL XZ DJ MRG RAB JCB. Contributed reagents/materials/analysis tools: LA AJJ KAB CCH MAF MRP DW SKK CC MRG CSC. Wrote the paper: DML LA DAW RAB JCB.